‘Readily Available’ Biomarkers May Predict Survivors at Risk for Cardiomyopathy

This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.